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Introduction: Alpha-fetoprotein (AFP) is an oncofetal protein produced by hepatocellular carcinoma (HCC). AFP level can
also be elevated in other neoplastic or non-neoplastic conditions. An elevated AFP level has high diagnostic significance for
HCC; at a level of >200 ng/mL, the probability of HCC is >90%. The aim of the present paper is to report a patient who
underwent curative resection of HCC, who had a persistently elevated AFP level postoperatively but did not develop
recurrence during a 2-year follow-up period. A review of the literature is also presented.
Case report: An 82-year-old male was referred following a computed tomography scan showing a 160 mm diameter mass
in the left lobe of the liver. This huge mass was diagnosed as HCC, arising in the absence of cirrhosis or viral hepatitis. After
tumor removal, the patient’s high AFP level persisted for 2 years.
Conclusion: As steatosis was the only pathological change in the remnant liver, this may have caused the persistently
elevated AFP level in this patient.
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Hepatocellular carcinoma (HCC) is commonly associated
with hepatitis B or C virus infection, and is particularly fre-
quent in patients with cirrhosis [1]. HCC arising in a normal
liver without cirrhosis or hepatitis is rare, with few reports in
the literature [2-4].
HCC causes 1 million deaths every year, making it the fifth
most common malignancy worldwide, and the incidence is
increasing [5-8]. The current standard of care in patients
with cirrhosis includes HCC screening with six-monthly
measurements of alpha-fetoprotein (AFP) level together with
abdominal ultrasonography or computed tomography (CT)
[9]. AFP is an oncofetal protein produced by HCC, but AFP* Correspondence: idicarlo@unict.it
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reproduction in any medium, provided the orlevel can also be elevated in other neoplastic or non-neoplas-
tic conditions [1,10,11]. An elevated AFP level has high diag-
nostic significance for HCC. When the AFP level is
>200 ng/mL, the probability of HCC is >90% [12].
If the tumor is resectable, surgery is considered to be the
curative treatment choice [5,13]. Postoperative recurrence is
common, and measurement of AFP level is considered to be
an extremely important screening test for the early detection
of recurrence [14].
The aim of the present paper is to report a patient with a
normal liver who underwent curative resection of HCC, fol-
lowed by a persistently elevated AFP level during two years
of follow-up without recurrence. A review of the literature is
also presented.
Case presentation
An 82-year-old male was referred to us after CT scanning
showed a 160 mm diameter mass in the left lobe of thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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displaced the gallbladder laterally. He was diagnosed with
HCC, arising in the absence of cirrhosis or viral hepatitis.
In 2007, he underwent his first CT scan, which showed
hepatic steatosis and a normal-sized liver without focal
lesions. In 2009, he was diagnosed with non-Hodgkin’s
lymphoma which was treated with allopurinol, pyridoxine,
and folinic acid.
In March 2009, he underwent the CT scan, which
showed the hepatic mass and resulted in his referral
to us. Magnetic resonance imaging was performed in
April 2009, and showed an enlarged liver with a 168
mm mass in segments 2 and 3. He was diagnosed with
HCC, and surgery was scheduled. He was in good nu-
tritional condition, with no ascites or coagulopathy.
Preoperative serum bilirubin and albumin levels were
normal, and AFP level was 21 ng/mL (normal 0 to
7.22 ng/mL). He underwent open resection in April
2009. The tumor occupied all of liver segments 2 and
3, and was adherent to the stomach. The right lobe of
the liver was normal in appearance. A left hepatic lob-
ectomy was performed. Histological examination ofFigure 1 Computed tomography scan of the tumor in liver segmentsthe surgical specimen showed hepatocellular carcin-
oma with a solid trabecular pattern, and thick fibrotic
septa which extended into the normal hepatic tissue at
the resection margin (Figure 2). There was diffuse
steatosis of the surrounding liver parenchyma
(Figure 3).
In August 2009, at the first postoperative follow-up,
his serum AFP level was 16 ng/mL. Abdominal CT
and positron emission tomography (PET) scans
showed no evidence of tumor recurrence. Serum AFP
levels were 15.7 ng/mL in November 2009 and 8.6 ng/
mL in February 2010. A CT scan in March 2010 and
PET scan in April 2010 did not show any evidence of
recurrence. AFP levels were 17.2 ng/mL in May 2010;
18.4 ng/mL in September 2010; 15.4 ng/mL in Decem-
ber 2010; 16.2 ng/mL in March 2011; 3.69 ng/mL in
June 2011; 3.58 ng/mL in September 2011; and
3.4 ng/ml in December 2011 (Figure 4). The patient
was investigated for other conditions that might cause
elevated AFP levels. Testicular, gastric, pancreatic, bil-
iary and lung cancer, and spherocytosis and tyrosine-
mia, were excluded.2 and 3. (A) Pre-contrast phase; (B) Arterial phase; (C) Portal phase.
Figure 2 Upper right corner: hepatocellular carcinoma (arrow). Left: preserved laminar hepatic architecture with mild perisinusoidal
lymphocytic infiltration.
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AFP is an oncofetal protein of approximately 72 kDa. AFP
is produced by normal gastrointestinal cells, yolk sac cells,
and fetal hepatocytes immediately after birth. Serum AFP
level decreases gradually after birth, to <10 ng/mL within
300 days [15]. Some reports indicate that healthy indivi-
duals may have AFP levels of up to 20 ng/mL, and levels
above this are considered to indicate the possibility of liver
disease [16]. The normal range is given as 0 to 7.22 mg/
mL in our laboratory and, in the current case, the AFP
level was persistently above this range.
AFP level may be elevated in patients with chronic
liver disease such as hepatitis or cirrhosis, or patients
with drug or alcohol abuse, but in these cases the level is
usually <100 ng/mL [11,17]. The presence of a focalFigure 3 Normal hepatic tissue with diffuse steatosis (arrows).hypervascular lesion >2 cm in diameter associated with
a serum AFP level of >400 ng/mL is considered diagnos-
tic for HCC [18]. The Italian and the American Associ-
ation for the Study of Liver Diseases guideline considers
an AFP level of ≥200 ng/mL to be diagnostic for HCC
[11] .
AFP level is used for both early diagnosis and monitor-
ing of HCC, but it is estimated that the false-negative
rate when using AFP level as a single parameter may be
as high as 40%, especially in patients with early HCC.
AFP level may remain in the normal range in 15 to 30%
of patients with HCC [19]. A high preoperative AFP level
is associated with intrahepatic metastasis, early recur-
rence, and a poor survival rate after hepatectomy. The
ratio of AFP level to tumor diameter may be a better
Figure 4 Serum AFP levels during follow-up (normal 0 to 7.22 ng/mL).
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serum AFP level alone [20].
AFP level can be used for postoperative monitoring,
especially when it is elevated in the early postoperative
period. Recurrent HCC is expected to have the same bio-
activity as the primary tumor. Some patients with an ele-
vated AFP level at initial HCC presentation do not have
an elevated level with recurrence; this may be because
the recurrence is actually a second primary tumor with
chromosomal aberration [21].
Exacerbation of infectious hepatitis or cirrhosis may
also cause a transiently elevated AFP level [22].
AFP levels vary during the different phases of the under-
lying disease, but do not follow a regular pattern. As AFP
levels vary between patients and diseases, it is possible that
two patients with the same disease, who are in the same
phase of disease progression, have differences in their AFP
levels; one could have an elevated AFP level, while the
other could have an AFP level close to zero [11,22].
The persistently elevated AFP level after hepatectomy in
the current patient cannot be explained by exacerbation of
an underlying disease, because he did not have hepatitis or
cirrhosis. Incomplete resection of the tumor margins
might be suspected, but pathological examination showed
adequate margins, and curative resection was confirmed
by the absence of recurrence on CT and PET scans.
As well as being produced by the tumor, AFP may play
a role in tumor growth, as preclinical evidence has
shown that AFP may have a modulatory effect on hepa-
toma cells [20].
Many studies have reported that an elevated AFP level is
an adverse prognostic factor in both early and advancedstages of HCC. An AFP level of >10,000 ng/mL is asso-
ciated with a three-year survival rate of 40%, and an AFP
level of 200 to 10,000 ng/mL is associated with a three-
year survival rate of 70% [20]. In HCC patients with a low
AFP level (20 to 100 ng/mL), the AFP level may decrease
and falsely indicate a response to treatment, due to the low
specificity of AFP for HCC in this range [20].
AFP levels are useful for evaluating the response to treat-
ment and for detecting recurrence [11]. In cases of HCC
arising in a liver without cirrhosis or viral hepatitis, these
variations can be more evident, and normal cut-off values
may be lower. Lubrano et al. [3] reported a study of 20
patients with this rare presentation of HCC, and found
that only half had elevated AFP levels. As the current pa-
tient had the same type of disease as those evaluated in the
study by Lubrano et al., his persistently elevated AFP level
after hepatectomy, which was above the normal range but
not as high as the cut-off value, was particularly suspicious
for recurrent HCC and had to be carefully evaluated.
Although the literature describing HCC arising in a liver
without cirrhosis or viral hepatitis is inconsistent, existing
studies do agree on some aspects of this disease. The most
important aspect is the difference between the natural
courses of HCC arising in normal liver parenchyma and in
cirrhotic liver. Liver cirrhosis and portal hypertension result
in a reduced survival rate in HCC patients, especially those
treated in the early stage of the disease (TNM stage I)
[2,3,23]. It has also been reported that HCC in non-cirrhotic
livers is more frequent in men than in women, and that
the tumors are larger than those in cirrhotic livers [3,23].
In patients with HCC arising in both non-cirrhotic and cir-
rhotic livers, the main cause of postoperative death is
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after surgery [23].
The frequency of postoperative recurrence is similar in
patients with hepatitis B or C virus infection and those
without, but patients without chronic hepatitis have better
liver function and tend to get fewer nodules in the remnant
liver, which enables easier resection of recurrences [4].
Extensive resection with a wide tumor margin is tech-
nically easier in HCC arising in a non-cirrhotic liver than
a cirrhotic liver, resulting in a lower probability of recur-
rence and a better prognosis [23-26].
Elevated AFP level is not always associated with liver
disease. Other conditions (neoplastic or non-neoplastic)
can also cause a transient or persistent elevation in APF
level, and should be considered in the differential diag-
nosis. Non-seminoma testis cancer can cause an elevated
AFP level in association with elevated levels of other
tumor markers such as beta-human chorionic gonado-
tropin and lactate dehydrogenase [27,28]. A pure semi-
noma may also produce AFP, but should then be
managed as a non-seminoma cancer [28]. Approximately
2 to 6% of gastric cancers produce AFP, and these are gen-
erally associated with high rates of venous invasion, lymph
node metastasis and liver metastasis, and an extremely
poor survival rate, compared with other gastric cancers
[29]. Hepatoid carcinoma is a primary extrahepatic neo-
plasm that has similar features to HCC in terms of immu-
nohistochemistry, morphology, and biological behavior.
Many patients with hepatoid carcinoma have an elevated
serum AFP level at presentation. These tumors most
commonly arise in the stomach, but a small proportion
arise in the pancreas [30]. Approximately 2% of lung
cancers produce AFP. AFP-producing lung cancers are
usually adenocarcinomas, with a small proportion being
large-cell carcinomas and squamous-cell carcinomas [31].
Pregnancy may cause an elevated AFP level, especially
when the pregnancy is complicated by an abnormality
such as a spinal cord defect [32].
Obesity and diabetes seem to be associated with HCC.
These conditions are risk factors for cirrhosis, but their
role in the non-cirrhotic liver is more controversial [26].
Hepatic steatosis can also cause a high AFP level. Stea-
tosis can be divided into two phases; during the first
phase, lipids accumulate in the hepatocytes, and in the
second phase, factors such as oxidative stress, proinflam-
matory cytokines, mitochondrial dysfunction, and lipid
peroxidation damage the hepatocytes and cause inflam-
mation and fibrosis. In 2009, a study by Babali et al. [33]
found that AFP level was associated with the grade of
steatosis. In patients with steatosis, AFP production may
be stimulated by cytokines, or may result from altered
interactions between hepatocytes [33].
In our patient, steatosis was the only abnormality of the
hepatic parenchyma detected on pathological examination,and was the only condition that could have caused the per-
sistently elevated AFP level, as laboratory tests and imaging
results eliminated all other possible causes.
Non-alcoholic steatohepatitis (NASH) can induce HCC
by unknown mechanisms, in which insulin resistance
seems to play an important role. Insulin resistance
causes inhibition of hepatic mitochondrial fatty acid oxi-
dation and stimulation of microsomal peroxidases,
resulting in increased intracellular concentrations of fatty
acids, which may cause oxidative DNA damage [34].
NASH can evolve into cirrhosis before giving rise to
HCC, but the cirrhosis stage is not necessary, as there are
many reported cases in the literature of HCC arising dir-
ectly from NASH. NASH therefore has to be considered
as a possible cause when HCC arises in a non-cirrhotic
liver [34,35]. HCC arising in NASH may occur without an
elevated AFP level [36].
Another rare condition that may cause an elevated AFP
level in a patient with a normal liver is hereditary persist-
ence of AFP (HPAFP), which is asymptomatic. Only 19
families with HPAFP have been described over the past
28 years, many of whom also had urological disorders (ma-
lignant or benign). HPAFP can, therefore, also be consid-
ered in patients with an unexplained high AFP level
[37,38].
Conclusions
In conclusion, we present a case in which hepatic steato-
sis is the only possible cause of the persistently elevated
AFP level after curative resection of HCC.
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